VCYT vs PAHC vs NEOG vs IDXX vs BIO

For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.

4% revenue growth year-over-year, versus -3. 2% for Neogen Corporation (NEOG). Bio-Rad Laboratories, Inc. (BIO) offers the better valuation at 9. 2x trailing P/E (25. 0x forward), making it the more compelling value choice. Analysts rate Veracyte, Inc. (VCYT) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bio-Rad Laboratories, Inc.

(BIO) is the cheapest at 9. 2x versus Veracyte, Inc. at 49. 7x. On forward P/E, Phibro Animal Health Corporation is actually cheaper at 14. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Phibro Animal Health Corporation wins at 1. 90x versus IDEXX Laboratories, Inc. 's 2. 68x — a reasonable growth-adjusted valuation.

Over the past 5 years, Phibro Animal Health Corporation (PAHC) delivered a total return of +66.

0%, compared to -80. 6% for Neogen Corporation (NEOG). Over 10 years, the gap is even starker: VCYT returned +632. 6% versus NEOG's -50. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bio-Rad Laboratories, Inc.

(BIO) is the lower-risk stock at 0. 92β versus Veracyte, Inc. 's 1. 69β — meaning VCYT is approximately 83% more volatile than BIO relative to the S&P 500. On balance sheet safety, Veracyte, Inc. (VCYT) carries a lower debt/equity ratio of 3% versus 3% for Phibro Animal Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.

4% versus -3. 2% for Neogen Corporation (NEOG). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -114. 6% for Neogen Corporation. Over a 3-year CAGR, VCYT leads at 20. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bio-Rad Laboratories, Inc.

(BIO) is the more profitable company, earning 29. 4% net margin versus -122. 1% for Neogen Corporation — meaning it keeps 29. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus 1. 1% for NEOG. At the gross margin level — before operating expenses — VCYT leads at 69. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Phibro Animal Health Corporation (PAHC) is the more undervalued stock at a PEG of 1. 90x versus IDEXX Laboratories, Inc. 's 2. 68x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Phibro Animal Health Corporation (PAHC) trades at 14. 2x forward P/E versus 38. 3x for IDEXX Laboratories, Inc. — 24. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IDXX: 30. 6% to $747. 50.

In this comparison, PAHC (1.

1% yield) pays a dividend. VCYT, NEOG, IDXX, BIO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Phibro Animal Health Corporation (PAHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (1.

1% yield, +128. 6% 10Y return). Neogen Corporation (NEOG) carries a higher beta of 1. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PAHC: +128. 6%, NEOG: -50. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VCYT is a small-cap high-growth stock; PAHC is a small-cap high-growth stock; NEOG is a small-cap quality compounder stock; IDXX is a mid-cap quality compounder stock; BIO is a small-cap deep-value stock. PAHC pays a dividend while VCYT, NEOG, IDXX, BIO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.